Asebio and Aelmhu Positively Value the First Meeting of the Joint Committee for the Industry Strategy

The Strategic Plan for the Pharmaceutical Industry is receiving a very positive response in the biotech sector. In addition to the statements made by several participating entities, Asebio and Aelmhu have now joined in, considering that the first meeting of the Joint Committee of Ministries-Industry on the Pharmaceutical Industry Strategy 2024-2028 has been a good starting point, although its impact will also depend on its subsequent deployment.

According to Asebio, “the Joint Committee is a key element in the governance of the Pharmaceutical Industry Strategy 2024-2028, which was approved by the Council of Ministers on December 10. It is a roadmap that has been drawn up by an inter-ministerial working group in which the Ministries of Health and Finance have participated.”

Industry and Tourism; and Science, Innovation and Universities, together with the main employers’ associations of the pharmaceutical industry in Spain: Farmaindustria , AESEG , BioSim, AFAQUIM and AseBio, whose representatives, with the incorporation of AELMHU, constitute this Joint Committee.

With its participation in this first meeting of the Joint Committee of Ministries and Industry, AseBio “consolidates its participation in the Strategy and its governance”. The entity was represented by Cristina Nadal, second vice president of AseBio and executive director of Policy at MSD Spain; Ion Arocena, general director of AseBio; and Diego Moñux, member of the Board of Directors of AseBio and managing partner of SILO.

“We at AseBio welcome this strategy, which represents a unique opportunity for dialogue and the joint construction of a world-class biopharmaceutical industry,” the association said in a statement.

For AseBio, it is important that the deployment of the Strategic Plan allows for the articulation of the environment that the biotechnology sector requires to grow and develop

In this sense, “we advocate establishing the bases of a framework that makes our country attractive for companies to see Spain as a suitable country for the development and introduction of their technologies. We are talking about a system that accompanies companies based on technology ‘made in Spain’ to bring their innovations to the patient, which would establish an environment that would facilitate the attraction of investment and fuel the growth of the Spanish innovation ecosystem,” they indicated.

Along these lines, AseBio has offered its collaboration “to inform and train the biotechnology ecosystem on the novel procedures contemplated in the strategy, and thus allow SMEs to navigate the complex environment of access to their innovations in the NHS”. To this end, “we consider the new Health Technology Assessment System to be particularly relevant, as well as the early interaction procedures and collaborations to generate real-life knowledge that the Strategy proposes”.

AseBio highlighted its willingness to collaborate in the research, development and innovation pillar of the Strategy, which “we consider fundamental for the competitiveness of the Spanish biotechnology and pharmaceutical industry”. A pillar in which AseBio has been “working hand in hand with the Ministry of Science, Innovation and Universities for some time, as well as with its associated entities such as PERTE for Vanguard Health, CDTI and ISCIII , whom we thank for their collaboration”.

“The strategy should serve as an incentive to continue working to promote R&D&I in the sector with even greater ambition, and in this regard, AseBio offered its collaboration in three main areas: Firstly, to promote collaboration between biotechnology companies and those programs and initiatives where the Strategy identifies this need, through the organization of joint activities, conferences and programs. Secondly, we offered the collective intelligence of the association to design instruments that encourage activities that the Strategy identifies as ecosystem challenges. And, finally, we offered the events that AseBio organizes or co-organizes, such as Biospain and the Meeting of Biomedical Research Platforms, as a platform to promote interaction between public and private sector R&D&I.

Finally, in relation to the pillar of competitiveness, resilience and eco-sustainability of the industrial ecosystem and its supply chains, AseBio has shown its willingness to collaborate in the evaluation of the results of Profarma , proposed in the strategy, with the aim of guiding the updating and adaptation of the program, where we hope to be able to contribute with the contributions of the sector.

Furthermore, in terms of regulation and strategic autonomy, we offer to collaborate in the working group on productive capacities and in the development of RECAPI.

For its part, the Spanish Association of Orphan and Ultra-Orphan Drug Laboratories (Aelmhu) , which represents pharmaceutical companies that research, develop and market innovative therapies to treat rare and ultra-rare diseases , “positively values ​​and appreciates our incorporation and participation in the Pharmaceutical Industry Plan.”

Aelmhu believes that “we are facing a great opportunity to move towards a more inclusive, innovative and sustainable model, which takes into account the needs of patients with rare diseases.” In this regard, they highlight the strategic recognition of advanced therapies, which in the vast majority of cases are treatments intended to address rare diseases.

Regarding the first meeting of the Joint Committee, whose objective is based on the collaboration of all the parties involved, Aelmhu “consolidates its participation in the Strategy with proposals that serve as a lever to address the needs of patients with rare diseases and transfer the vision and knowledge of the companies that research and develop innovative treatments, in order to increase and speed up the arrival of these innovative medicines for patients.”

Aelmhu has made our recommendations and proposals available to the competent bodies in the various Ministries, with the aim of guaranteeing early access to the treatments that patients need and for “Spain to consolidate itself as a country committed to addressing these diseases.”

__

(Featured image by Alex Azabache via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in diariofarma. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us